Alnylam Pharmaceuticals (ALNY) EBITDA (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of EBITDA data on file, last reported at $231.4 million in Q2 2026.

• Quarterly EBITDA rose 1528.74% year-over-year to $231.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $999.8 million (up 654.86% YoY) and the FY2025 annual result came in at $501.6 million, up 383.56% from the prior year.
• EBITDA fell to $231.4 million in Q2 2026, from $268.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $368.0 million in Q3 2025 to a low of -$258.0 million in Q3 2022.
• A 5-year average of -$13.5 million and a median of -$60.2 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA sank 135.96% — and 2026, when it soared 1528.74%.
• Tracing ALNY's EBITDA over 5 years: stood at -$188.6 million in 2022, then jumped by 38.28% to -$116.4 million in 2023, then climbed by 9.66% to -$105.2 million in 2024, then soared by 225.26% to $131.7 million in 2025, then jumped by 75.71% to $231.4 million in 2026.
• The last three EBITDA figures came in at $231.4 million (Q2 2026), $268.6 million (Q1 2026), and $131.7 million (Q4 2025), per Business Quant data.